{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:39:09Z","timestamp":1793039949390,"version":"4.5.0"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Malignant melanoma is characterized by high heterogeneity, aggressive metastatic potential, and a profoundly immunosuppressive \u201ccold\u201d tumor microenvironment, contributing to broad therapeutic resistance and suboptimal responses to immunotherapy. Conventional PD-1 inhibitors yield an ORR of only 38%. As an emerging class of immunotherapeutic agents, oncolytic viruses (OV) induce ICD, promoting the release of DAMPs and activating innate immune pathways such as cGAS-STING, thereby transforming \u201ccold\u201d tumors into \u201chot\u201d phenotypes and eliciting robust anti-tumor responses. Mechanistically, OV therapy increases the proportion of CD103\n                    <jats:sup>+<\/jats:sup>\n                    dendritic cells (DCs) in lymph nodes from 5% to 25% and enhances DC\u2013tumor synapse formation by 300%, facilitating efficient cross-presentation of tumor antigens and T-cell priming. Clinically, T-VEC combined with pembrolizumab achieves a 48.6% ORR with grade \u22653 AEs occurring in &amp;lt;20% of patients\u2014superior to either monotherapy or conventional chemoradiotherapy. Nonetheless, OV therapy faces challenges including tumor heterogeneity, core mechanistic limitations, viral shedding risks, and regulatory hurdles. Over the next 5\u201310 years, single-cell RNA sequencing is expected to unravel molecular heterogeneity in melanoma, while CRISPR\/Cas systems may enable the design of tailored OV to overcome resistance. Additional strategies such as serotype switching, JAK\/STAT inhibition, and arming OV with hyaluronidase or STING agonists are under investigation to overcome immune and stromal barriers. Integration of artificial intelligence with biomarkers\u2014such as neutralizing antibody titers, ISG expression, and STING methylation\u2014may further enable personalized OV-based therapies. This review discusses OV therapy\u2019s mechanisms, clinical impact, and future prospects in melanoma treatment.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1653683","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T05:35:04Z","timestamp":1756964104000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Opportunities, challenges, and future perspectives of oncolytic virus therapy for malignant melanoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Jia-Wen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Jun","family":"Xun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00173","article-title":"Microenvironment-driven dynamic heterogeneity and phenotypic plasticity as a mechanism of melanoma therapy resistance","volume":"8","author":"Ahmed","year":"2018","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1176994","article-title":"Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors","volume":"14","author":"Ding","year":"2023","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/s41467-023-36979-y","article-title":"The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat Commun"},{"key":"B5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","article-title":"Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy","volume":"6","author":"Tang","year":"2021","journal-title":"Signal transduction targeted Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5740","DOI":"10.1038\/s41467-023-41101-3","article-title":"Activation of melanocortin-1 receptor signaling in melanoma cells impairs T cell infiltration to dampen antitumor immunity","volume":"14","author":"Cui","year":"2023","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e138772","DOI":"10.1172\/jci.insight.138772","article-title":"IL-32\u03b3 potentiates tumor immunity in melanoma","volume":"5","author":"Gruber","year":"2020","journal-title":"JCI Insight"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.008","article-title":"The immune revolution: A case for priming, not checkpoint","volume":"33","author":"Vonderheide","year":"2018","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00436","article-title":"STAT3 contributes to oncolytic newcastle disease virus-induced immunogenic cell death in melanoma cells","volume":"9","author":"Shao","year":"2019","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2016.8","article-title":"Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells","volume":"23","author":"Takasu","year":"2016","journal-title":"Cancer Gene Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953410","article-title":"Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements","volume":"13","author":"Yun","year":"2022","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR drug discovery: new agents, targets and indications","volume":"16","author":"Hauser","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00683","article-title":"Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment","volume":"11","author":"Shi","year":"2020","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41571-019-0224-2","article-title":"HDAC inhibitors tested in phase III trial","volume":"16","author":"Romero","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s12916-022-02574-z","article-title":"SIRP\u03b1 antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment","volume":"20","author":"Kong","year":"2022","journal-title":"BMC Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.05.095","article-title":"Current and emerging intralesional immunotherapies in cutaneous oncology","volume":"91","author":"Stull","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010662","article-title":"Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia\/Ib trial results and biomarker insights[J","volume":"13","author":"Wang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-024-01349-x","article-title":"Recombinant human adenovirus type 5 promotes anti-tumor immunity via inducing pyroptosis in tumor endothelial cells","volume":"45","author":"Wang","year":"2024","journal-title":"Acta pharmacologica Sin"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.3c06501","article-title":"Revolutionizing cancer treatment: unleashing the power of viral vaccines, monoclonal antibodies, and proteolysis-targeting chimeras in the new era of immunotherapy","volume":"9","author":"Mohite","year":"2024","journal-title":"ACS omega"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.3390\/cancers16111957","article-title":"Intralesional and infusional updates for metastatic melanoma","volume":"16","author":"Dugan","year":"2024","journal-title":"Cancers"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e008025","DOI":"10.1136\/jitc-2023-008025","article-title":"Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy","volume":"12","author":"Wang","year":"2024","journal-title":"J immunotherapy Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.3390\/v16121944","article-title":"Human melanoma and glioblastoma cells express cathepsins supporting reovirus moscow strain infection","volume":"16","author":"Ammour","year":"2024","journal-title":"Viruses"},{"key":"B25","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41598-024-82331-9","article-title":"Oncolytic alphavirus-induced extracellular vesicles counteract the immunosuppressive effect of melanoma-derived extracellular vesicles","volume":"15","author":"Bhatt","year":"2025","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12964-024-01860-y","article-title":"cGAS\/STING in skin melanoma: from molecular mechanisms to therapeutics[J","volume":"22","author":"Mahin","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B27","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41392-024-02029-2","article-title":"Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial","volume":"9","author":"Liu","year":"2024","journal-title":"Signal transduction targeted Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-025-00882-z","article-title":"Ferroptosis enhances the therapeutic potential of oncolytic adenoviruses KD01 against cancer","volume":"32","author":"Li","year":"2025","journal-title":"Cancer Gene Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12935-024-03424-z","article-title":"Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments","volume":"24","author":"Yan","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/v13071200","article-title":"The effect of herpes simplex virus-type-1 (HSV-1) oncolytic immunotherapy on the tumor microenvironment[J","volume":"13","author":"Uche","year":"2021","journal-title":"Viruses"},{"key":"B31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s40425-019-0682-1","article-title":"Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1[J","volume":"7","author":"Thomas","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1532763","DOI":"10.1080\/2162402X.2018.1532763","article-title":"Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model[J","volume":"8","author":"Kuryk","year":"2019","journal-title":"Oncoimmunology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1111119","article-title":"Case report: Therapeutic potential of T-VEC in combination with MEK inhibitors in melanoma patients with NRAS mutation[J","volume":"13","author":"Simon","year":"2023","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"15290","DOI":"10.1038\/s41598-021-94483-z","article-title":"Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis[J","volume":"11","author":"AuYeung","year":"2021","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma[J","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01346","article-title":"RP1 combined with nivolumab in advanced anti-PD-1-failed melanoma (IGNYTE)[J","volume":"43","author":"Wong","year":"2025","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2046","article-title":"Pilot study of ONCOS-102 and pembrolizumab: remodeling of the tumor microenvironment and clinical outcomes in anti-PD-1-resistant advanced melanoma[J","volume":"29","author":"Shoushtari","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma[J","volume":"41","author":"Chesney","year":"2023","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.877434","article-title":"Risk of adverse events in cancer patients receiving nivolumab with ipilimumab: A meta-analysis[J","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0213","article-title":"Successful treatment with carboplatin and paclitaxel in melanoma progression after immune-related adverse events[J","volume":"15","author":"D\u00fclgar","year":"2023","journal-title":"Immunotherapy"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.571135","article-title":"Comparative risks of high-grade adverse events among FDA-approved systemic therapies in advanced melanoma: systematic review and network meta-analysis[J","volume":"10","author":"Huang","year":"2020","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020221","article-title":"Current melanoma treatments: where do we stand?[J","volume":"13","author":"Moreira","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"102016","DOI":"10.1016\/j.xcrm.2025.102016","article-title":"Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma","volume":"6","author":"Monberg","year":"2025","journal-title":"Cell Rep Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"217616","DOI":"10.1016\/j.canlet.2025.217616","article-title":"Clinical development of immuno-oncology therapeutics","volume":"617","author":"Wang","year":"2025","journal-title":"Cancer Lett"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.36922\/mi.3445","article-title":"Factors associated with response to talimogene laherparepvec in the treatment of advanced melanoma[J","volume":"1","author":"Balasubramanian","year":"2024","journal-title":"MI"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2024.101009","article-title":"Changes in AXL and\/or MITF melanoma subpopulations in patients receiving immunotherapy[J","volume":"24","author":"Willemsen","year":"2024","journal-title":"Immunooncol Technol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1591875","article-title":"Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma[J","volume":"8","author":"Bommareddy","year":"2019","journal-title":"Oncoimmunology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.834841","article-title":"Talimogene laherparepvec: moving from first-in-class to best-in-class[J","volume":"9","author":"Kaufman","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.03.017","article-title":"Chimeric oncolytic adenovirus to break away from neutralizing antibodies","volume":"32","author":"Sanchez Gil","year":"2024","journal-title":"Mol therapy: J Am Soc Gene Ther"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e20221721","DOI":"10.1084\/jem.20221721","article-title":"PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway","volume":"221","author":"Hodgins","year":"2024","journal-title":"J Exp Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"7165","DOI":"10.1038\/s41467-024-51496-2","article-title":"Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade","volume":"15","author":"Holzgruber","year":"2024","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e008431","DOI":"10.1136\/jitc-2023-008431","article-title":"An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy","volume":"12","author":"Wang","year":"2024","journal-title":"J immunotherapy Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e008880","DOI":"10.1136\/jitc-2024-008880","article-title":"Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival","volume":"12","author":"Bommareddy","year":"2024","journal-title":"J immunotherapy Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e008307","DOI":"10.1136\/jitc-2023-008307","article-title":"Oncolytic varicella-zoster virus engineered with ORF8 deletion and armed with drug-controllable interleukin-12","volume":"12","author":"Jiang","year":"2024","journal-title":"J immunotherapy Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ebiom.2019.07.066","article-title":"Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma[J","volume":"47","author":"Andtbacka","year":"2019","journal-title":"EBioMedicine"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.09.012","article-title":"Durable melanoma control following disseminated talimogene laherparepvec herpetic infection[J","volume":"29","author":"Shmuylovich","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B57","volume-title":"Design and analysis of shedding studies for virus or bacteria-based gene therapy and oncolytic products: guidance for industry","year":"2015"},{"key":"B58","volume-title":"Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials","year":"2025"},{"key":"B59","volume-title":"Regulatory update of cell and gene therapy products in Japan","author":"Maruyama","year":"2024"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11091448","article-title":"Oncolytic viruses: an inventory of shedding data from clinical trials and elements for the environmental risk assessment[J","volume":"11","author":"Onnockx","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B61","article-title":"Determining the need for and content of environmental assessments for gene therapies, vectored vaccines, and related recombinant viral or microbial products: guidance for industry","year":"2015"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673283943240227104122","article-title":"Immunotherapy of human melanoma: past, present, future","volume":"32","author":"Mortezaee","year":"2024","journal-title":"Curr medicinal Chem"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1325558","article-title":"Recombinant Newcastle disease viruses expressing immunological checkpoint inhibitors induce a pro-inflammatory state and enhance tumor-specific immune responses in two murine models of cancer","volume":"15","author":"Santry","year":"2024","journal-title":"Front Microbiol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16346-x","article-title":"Genetic factors associated with clinical response in melanoma patients treated with talimogene laherparapvec: A single-institution retrospective analysis","volume":"32","author":"Sierra-Davidson","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B65","article-title":"New data with RP1 plus nivolumab in PD-1\u2013refractory melanoma build on positive findings","author":"Doherty","year":"2024","journal-title":"OncLive (June"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14781","article-title":"Environmental risk assessment of advanced therapies containing genetically modified organisms in the EU[J","volume":"87","author":"Whomsley","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"21560","DOI":"10.1038\/s41598-022-26030-3","article-title":"Effects of pre-existing anti-adenovirus antibodies on transgene expression levels and therapeutic efficacies of arming oncolytic adenovirus[J","volume":"12","author":"Ono","year":"2022","journal-title":"Sci Rep"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.971674","article-title":"The gamble between oncolytic virus therapy and IFN[J","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12943-020-01290-7","article-title":"The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?[J","volume":"19","author":"Ballotti","year":"2020","journal-title":"Mol Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-02118-7","article-title":"An oncolytic virus-T cell chimera for cancer immunotherapy","volume":"42","author":"Chen","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03411-x","article-title":"Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1\/2 trial","volume":"31","author":"Dummer","year":"2025","journal-title":"Nat Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00841-0","article-title":"Therapeutic strategies in BRAF V600 wild-type cutaneous melanoma","volume":"25","author":"Haugh","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/biomedicines13010108","article-title":"Oncolytic viruses and immunotherapy for the treatment of uveal melanoma and retinoblastoma: the current landscape and novel advances","volume":"13","author":"Kulbay","year":"2025","journal-title":"Biomedicines"},{"key":"B74","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3390\/ph17020214","article-title":"A review of current and pipeline drugs for treatment of melanoma","volume":"17","author":"Natarelli","year":"2024","journal-title":"Pharm (Basel Switzerland)"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/nm1193","article-title":"Auditory hair cell replacement and hearing improvement by Atoh1 gene therapy in deaf mammals[J","volume":"11","author":"Izumikawa","year":"2005","journal-title":"Nat Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108611","article-title":"Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations[J","volume":"256","author":"Shirazi","year":"2024","journal-title":"Pharmacol Ther"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03246","article-title":"Clinical responses of oncolytic coxsackievirus A21 (V937) in patients with unresectable melanoma[J","volume":"39","author":"Andtbacka","year":"2021","journal-title":"J Clin Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.777775","article-title":"Perspectives for combining viral oncolysis with additional immunotherapies for the treatment of melanoma[J","volume":"9","author":"Cerqueira","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B79","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers[J","volume":"4","author":"Ranki","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1038\/s41598-021-81831-2","article-title":"Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs[J","volume":"11","author":"B\u00e9guin","year":"2021","journal-title":"Sci Rep"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23967","article-title":"Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients[J","volume":"9","author":"Taipale","year":"2018","journal-title":"Oncotarget"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.2340\/1651-226X.2025.42515","article-title":"Circulating tumor DNA for surveillance in high-risk melanoma patients: a study protocol[J","volume":"64","author":"Obinah","year":"2025","journal-title":"Acta Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1653683\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T05:35:06Z","timestamp":1756964106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1653683\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":82,"alternative-id":["10.3389\/fimmu.2025.1653683"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1653683","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"article-number":"1653683"}}